APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 1315/HR 3777 the Drug Price Competition Act of 2009 S. 369, the Preserve Access to Affordable Pharmaceuticals Act SA 4361 to HR 4213 concerning market blockages caused by pharmaceutical patent settlements HR 759, Food and Drug Administration Globalization Act of 2009 Draft legislation concerning pharmaceutical manufacturing facility inspections Establishment of a generic drug user fee program
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.